OHMX.bio

OHMX.bio is a Belgian contract research organization (CRO) that specializes in cutting-edge multi-omics technologies for pharmaceutical, biotechnology and clinical research. Founded in 2019 as a spin-off from Ghent University, the company is rooted in the academic excellence and innovation ecosystem of Ghent, where it leverages academic expertise in high-throughput analysis methods. It describes itself as a "Study Design Company (CRO)" offering tailored project management that spans sample preparation, advanced data analysis and sophisticated reporting across transcriptomics, translatomics, proteomics and (epi)genetics. The company positions itself as a partner for "innovative OMICS solutions," serving clients across discovery and (pre)clinical studies. Its service portfolio is organized around several application areas: expression analyses (including RNA sequencing as an alternative to targeted qPCR), clinical and research diagnostics, quality control of biologics (using long-read sequencing to examine insertion sites and off-target effects), and single-cell sequencing. It also offers a full range of biomarker discovery and development services divided into five main categories, covering discovery and non-clinical biomarkers, clinical biomarkers, MRD (minimal residual disease) testing, and related offerings, designed to support biopharma, biotechnology and clinical research clients at every stage of their projects. On the technology side, OHMX.bio provides proteomics services built on state-of-the-art mass spectrometry and advanced bioinformatics, including immunopeptidomics, phosphoproteomics and glycoproteomics. Its in-house optimized ribosome profiling service enables genome-wide assessment of the translated portion of mRNAs, bridging the gap between transcriptomics and proteomics. The company markets itself as offering "a solution to every -omics question," whether for a single question or a multi-omics approach. OHMX.bio reports more than 90 completed projects, over 190 solutions offered to progress research and clinical trials, and more than 40 years of combined experience in sequencing solutions. Its milestones include its establishment as a Ghent University spin-off in 2019, a move to the Proeftuinstraat facility in 2021, its first clinical study in 2023, joining the Anacura group in 2024, and an expansion to Switzerland in 2025 to support a growing client base and expand its multi-omics services across Europe. The company is headquartered in the Ghent area of Belgium and operates primarily across Europe.

OHMX.bio was founded in 2019 as a spin-off from Ghent University, established to leverage academic expertise in high-throughput analysis methods. From its base in the Ghent innovation ecosystem, the company set out to apply advanced multi-omics technologies to pharmaceutical and biological research, bringing together wet-lab scientists, bioinformaticians and domain experts to deliver tailored projects. In 2021 the company relocated to a new facility on the Proeftuinstraat, a move intended to enhance its research and development capabilities. In 2023 OHMX.bio successfully conducted its first clinical study, which the company describes as a pivotal step in its commitment to advancing clinical research. In 2024 OHMX.bio joined the Anacura group, a step that expanded its services in multi-omics for drug discovery and diagnostics. The following year, in 2025, the company established a new office in Switzerland to support its growing client base and to expand its multi-omics services across Europe. Across its development, OHMX.bio has positioned itself as a "Study Design Company (CRO)" specializing in cutting-edge -omics technologies for extensive investigations covering discovery and (pre)clinical studies. Its service lines have grown to encompass transcriptomics, translatomics, proteomics and (epi)genetics, with tailored project management spanning sample preparation, advanced data analysis and sophisticated reporting. The company reports more than 90 completed projects, over 190 solutions offered to progress research and clinical trials, and more than 40 years of combined experience in sequencing solutions.

• 2025

  Established a new office in Switzerland to support a growing client base and expand multi-omics services across Europe.

• 2024

  Joined the Anacura group, expanding services in multi-omics for drug discovery and diagnostics.

• 2023

  Successfully conducted the first clinical study, marking a pivotal step in advancing clinical research.

• 2021

  Relocated to a new facility on the Proeftuinstraat, enhancing research and development capabilities.

• 2019

  Established as a spin-off from Ghent University, leveraging academic expertise in high-throughput analysis methods.

A premier Study Design Company (CRO) and partner for innovative OMICS solutions, offering a solution to every -omics question for biopharma, biotechnology and clinical research clients.

• Expression analyses (RNA sequencing)

  RNA sequencing unlocks all expressed genes in a sample, providing insights into gene activity, cellular functions and regulatory mechanisms.

• Clinical and research diagnostics

  Sequencing-based precise solutions for diagnosis or panel development, with projects registered in the company's quality system.

• Quality control of biologics

  Long-read sequencing to ensure the integrity and efficacy of biopharmaceutical products by examining insertion sites, off-target effects or other unwanted aberrations.

• Single-cell sequencing

  Examines specific cell populations to determine whether a therapy is working in the cells that matter.

• Translatomics (ribosome profiling)

  In-house optimized ribosome profiling service enabling genome-wide assessment of the translated portion of mRNAs, bridging transcriptomics and proteomics.

• Proteomics services

  Comprehensive suite using state-of-the-art mass spectrometry and advanced bioinformatics for protein expression, modification and interaction analysis.

• Immunopeptidomics

  Characterizes peptide fragments presented by the MHC, providing insights for immunotherapy and vaccine development.

• Phosphoproteomics

  Identification and quantification of phosphorylated proteins to decode regulatory networks in cancer, neurobiology and metabolic disorders.

• Glycoproteomics

  Advanced solutions for glycoproteins, which play critical roles in cellular communication, immune response and disease progression.

• Biomarker discovery and validation services

  Full range of biomarker discovery and development services across five categories, from discovery and non-clinical biomarkers to clinical biomarkers and MRD testing.

1. 1Multi-Omics CRO Services | Innovative OMICS solutionsohmx.bio
2. 2About us - Your partner for innovative OMICS solutions - OHMX.bioohmx.bio
3. 3Biomarker discovery & validation services | OHMX.bioohmx.bio
4. 4Proteomics services | Mass spectrometry & multi-omicsohmx.bio
5. 5OHMX.bio (Belgium)wikidata.org